Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sandostatin LAR Depot Clear all

Conditions: Liver, Cancer
Interventions: Thalidomide, alpha interferon, Thalidomide, interferon, Octreotide; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 2
States / cities: Albuquerque, New Mexico • Santa Fe, New Mexico

Conditions: Diarrhea, HIV Infections
Interventions: Octreotide; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 22
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Pancreatic Glucagonoma, Pancreatic Insulinoma, Pancreatic Polypeptide Tumor, Paraganglioma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Merkel Cell Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Somatostatin-Producing Neuroendocrine Tumor, Stage III Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma, Thyroid Gland Medullary Carcinoma
Interventions: Cixutumumab, Everolimus, Laboratory Biomarker Analysis, Octreotide Acetate, Pharmacological Study; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms
Interventions: Everolimus, Sandostatin LAR Depot; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 13
States / cities: Little Rock, Arkansas • Greenwood Village, Colorado • Stamford, Connecticut + 10 more

Conditions: Neuroendocrine Carcinoma
Interventions: Bevacizumab, Pertuzumab, Sandostatin LAR® Depot; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 9
States / cities: Fort Myers, Florida • Orlando, Florida • Augusta, Georgia + 6 more

Conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
Interventions: AMG 706, octreotide; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 112
States / cities: Berwyn, Illinois • Chicago, Illinois • Joliet, Illinois + 78 more

Conditions: Primary Insulin Hypersecretion, Obesity
Interventions: Sandostatin LAR Depot; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 3
States / cities: New Orleans, Louisiana • Memphis, Tennessee • Madison, Wisconsin

Conditions: Autonomic Failure, Orthostatic Hypotension
Interventions: Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham); Drug · Other · Dietary Supplement + 1 more
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Carcinoid Tumors
Interventions: Pasireotide (SOM230); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 4
States / cities: Los Angeles, California • Tampa, Florida • Iowa City, Iowa + 1 more

Conditions: Acromegaly
Interventions: Pasireotide (SOM230), Octreotide (Sandostatin); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more

Conditions: Acromegaly, Pituitary Neoplasm
Interventions: Sandostatin LAR Depot versus transsphenoidal surgery; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acromegaly
Interventions: Octreotide Implant, Sandostatin LAR Depot; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: Palo Alto, California • Denver, Colorado • Miami, Florida + 5 more

Conditions: Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
Interventions: Octreotide, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Carcinoid Syndrome
Interventions: Telotristat etiprate, Octreotide LAR Depot, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: SMS995, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Boston, Massachusetts • Rochester, Minnesota

Conditions: Diarrhea, HIV Infections
Interventions: Octreotide; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 18 more

Conditions: Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
Interventions: Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate, Recombinant Interferon Alfa-2b; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 493
States / cities: Mobile, Alabama • Fairbanks, Alaska • Fort Smith, Arkansas + 321 more

Conditions: Acromegaly
Interventions: Pasireotide, Octreotide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 14
States / cities: Los Angeles, California • Stanford, California • Gainesville, Florida + 9 more

Conditions: Prader-Willi Syndrome
Interventions: Octreotide, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 5 Years to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Neuroendocrine Tumors
Interventions: vatalanib; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Kenner, Louisiana

Conditions: Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
Interventions: octreotide acetate, Placebo; Drug · Other
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 112
States / cities: Mobile, Alabama • Phoenix, Arizona • Chico, California + 89 more

Conditions: Acromegaly
Interventions: Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more

Conditions: Breast Cancer
Interventions: octreotide acetate, tamoxifen citrate; Drug
Lead sponsor: NCIC Clinical Trials Group; Network
Eligibility: Up to 120 Years · Female only
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2010
U.S. locations: 2
States / cities: Duluth, Minnesota

Conditions: Liver Cancer
Interventions: octreotide acetate; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

Treatment of Orthostatic Hypotension in Autonomic Failure

Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors

Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Octreotide in Severe Polycystic Liver Disease

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Feasibility and Reproducibility of Barostat Assessments of Colorectal Sensation During Colorectal Distention and Its Pharmacological Modulation Using Octreotide

A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer